Oklahoma is currently home to 857 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cognitive-Behavioral Therapy for Children With Nightmares
NCT06033781
Recruiting
The goal of this clinical trial is to assess the efficacy of CBT-NC intervention to determine its impact on mental health and suicidality in children ages 6-17. The main aims are: Aim 1: Examine CBT-NC efficacy for improving nightmare distress and frequency in youth with chronic nightmares by comparing the treatment and waitlist group. Aim 2: Examine whether improvements in nightmares relate to fewer mental health problems for youth by determining by comparing the treatment and waitlist group.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
11/15/2023
Locations: University of Tulsa, Tulsa, Oklahoma
Conditions: Nightmare, Suicidal Ideation, Children, Only
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and imp... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
10/17/2023
Locations: St John Health System, Bartlesville, Oklahoma
Conditions: Iliofemoral; Thrombosis
Register for Updates
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
NCT01257269
Recruiting
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygo... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/10/2023
Locations: University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901, Oklahoma City, Oklahoma
Conditions: Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Register for Updates
Floatation-REST in Methamphetamine Use Disorder: A Pilot Study
NCT05799209
Recruiting
This early-stage trial aims to examine the feasibility, tolerability, and safety of Floatation-REST (Reduced Environmental Stimulation Therapy) or an active comparison condition in 50 individuals receiving treatment for Amphetamine-Type Substance Use Disorder.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
10/04/2023
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Amphetamine-Type Substance Use Disorder
Register for Updates
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
NCT02577302
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: University of Oklahoma health Sciences Center, Oklahoma City, Oklahoma
Conditions: Urinary Incontinence, Urge
Register for Updates
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
NCT05525247
Recruiting
This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2023
Locations: Selecxine Investigator site, Oklahoma City, Oklahoma
Conditions: Advanced Solid Tumor
Register for Updates
Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis
NCT05177107
Recruiting
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
09/05/2023
Locations: Nextstage Tulsa, Tulsa, Oklahoma
Conditions: Osteomyelitis, Diabetic Foot Osteomyelitis
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: DDSI, Oklahoma City, Oklahoma
Conditions: Ulcerative Colitis
Register for Updates
AltaValve Early Feasibility Study Protocol
NCT03997305
Recruiting
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Oklahoma Heart Hospital, Oklahoma City, Oklahoma
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05076942
Recruiting
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2023
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Register for Updates
Exercise-Induced Gut Permeability in Normal-weight Obesity
NCT05889767
Recruiting
Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/02/2023
Locations: 208 Nancy Randolph Davis, Oklahoma State University, Stillwater, Oklahoma
Conditions: Normal-weight Obesity, Obesity
Register for Updates
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
NCT04565015
Recruiting
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
Gender:
ALL
Ages:
Between 2 years and 16 years
Trial Updated:
05/15/2023
Locations: Oklahoma Institute of Allergy & Asthma Clinical Research, LLC, Oklahoma City, Oklahoma
Conditions: Primary Immune Deficiency
Register for Updates